Compare Gartner Inc (IT) vs Pfizer Inc (PFE) Price & Performance

Gartner (IT) trades at $185.6, up 0.42% today, with a bullish technical signal and strong earnings beats in recent quarters. The stock shows robust profitability with a 69.63% gross margin and 12% net income margin, though revenue growth has moderated. Recent news highlights Q2 2026 earnings exceeding expectations and raised full-year EPS guidance, driving positive investor sentiment.

Outlook is supported by valuation discounts (P/E 16.69) and high ROE (113.58%), but risks include consulting segment weakness and negative net cash flow trends. Analysts are mixed with a $172.80 consensus target, suggesting cautious optimism amid execution challenges.

Pfizer (PFE) trades at $26.74, up 2.06% today, with a bullish technical signal from moving averages and a consensus analyst price target of $27.86. Recent quarters show consistent earnings beats, though revenue has moderated from pandemic peaks. The company maintains a strong cash position of $20.48 billion (2024) and a dividend yield supported by a $0.43 per share payout. Key developments include a focus on obesity and oncology pipelines, with several catalysts expected in 2026.

The outlook balances a stable dividend and pipeline potential against post-COVID revenue normalization and patent cliff risks. Near-term upside exists if pipeline catalysts materialize, but investors face headwinds from competitive pressures and projected net income margin compression to 6.8% in 2026. The stock's valuation at a P/E of 35.21 appears elevated relative to earnings growth, warranting caution despite technical strength.